Caldera Health exists to help identify cancerous “hot spots”.
Caldera Health’s business goal is to replace the PSA test with a new, less intrusive, more reliable global standard,
using next-generation gene sequencing technology.
Caldera Health develops prostate cancer diagnostic tools that will fundamentally change the way clinicians detect and monitor the disease. The earlier a cancer is diagnosed, the better the patient’s chance of achieving a successful outcome. But the earliest signs of cancer are not visible to the naked eye: they’re a product of genetic changes and can only be identified at the molecular level. Gene-based technologies are the most capable tools for detecting these early changes.